No black box warning on record for Naphazoline Hci And Pheniramine Maleate

As of the latest FDA labeling reviewed, Naphazoline Hci And Pheniramine Maleate (NAPHAZOLINE HYDROCHLORIDE , PHENIRAMINE MALEATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Naphazoline Hci And Pheniramine Maleate medicine page for the complete safety profile.

Other warnings & precautions

Warnings: if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a physician. Do not use in children under 6 years of age unless directed by a physician. If this solution changes color or becomes cloudy, do not use. Overuse of this product may produce increased redness of

No black box warning on record for Naphazoline Hci And Pheniramine Maleate

Other warnings & precautions

Warnings: if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a physician. Do not use in children under 6 years of age unless directed by a physician. If this solution changes color or becomes cloudy, do not use. Overuse of this product may produce increased redness of

Naphazoline Hci And Pheniramine Maleate Black Box Warning

No black box warning on record for Naphazoline Hci And Pheniramine Maleate

Other warnings & precautions

Naphazoline Hci And Pheniramine Maleate Black Box Warning

No black box warning on record for Naphazoline Hci And Pheniramine Maleate

Other warnings & precautions